Carpal tunnel syndrome (CTS) is the most common peripheral entrapment neuropathy with
involving compression of the median nerve in the carpal tunnel. Although many conservative
managements of CTS, the effectiveness of these methods is insignificant or only persist for a
short duration. The platelet rich plasma (PRP) is a new and potential treatment for patients
with kinds of musculoskeletal disorders and recent reports showed being beneficial for
peripheral neuropathy in animal studies. Since 2014, four small clinical trials showed the
positive effect of PRP in peripheral neuropathy. Among these studies, two small trials showed
beneficial effect of PRP for patients with mild CTS. However, the definite clinical effect of
PRP for peripheral neuropathy from currently published studies is unclarified because these
studies enrolled a few patients and lacked long-term follow-up (no more than 6 months
follow-up).